Home Supplements That Start With G Goshajinkigan: Chemotherapy-Induced Neuropathy Support, Benefits, Dosage, and Risks

Goshajinkigan: Chemotherapy-Induced Neuropathy Support, Benefits, Dosage, and Risks

September 14, 2025 Modified date: September 14, 2025

Goshajinkigan (pronounced go-sha-jin-kee-gahn), often shortened to GJG, is a classic Kampo (Japanese traditional) herbal formula used to ease nerve-related symptoms such as numbness, tingling, cold sensitivity, and muscle cramps. Modern research has explored GJG most in two areas: diabetic nerve complications and chemotherapy-induced peripheral neuropathy (CIPN). The formula blends ten botanicals—including rehmannia, cinnamon bark, poria, and processed aconite root—aimed at improving circulation, modulating pain signaling, and supporting fluid balance. For patients on neurotoxic chemotherapy or those living with long-standing diabetes, GJG is sometimes used alongside standard care to reduce symptom burden. Typical dosing for the standardized extract is 7.5 g per day in three divided doses. While generally well tolerated in regulated products, the presence of processed aconite means safety and product quality matter. This guide explains what GJG is, how it may work, who might benefit, how to use it, and what to know about risks.

Key Insights

May lessen chemotherapy-related numbness and reduce long-term CIPN persistence in some settings.
Traditionally used for neuropathic discomfort and cold sensitivity; evidence in diabetes is mixed but suggests symptom relief in subsets.
Typical adult dose: 7.5 g/day of standardized extract (2.5 g three times daily) for 6–24 weeks, depending on goal.
Contains processed aconite root; use regulated products only and avoid combining with other aconite-containing remedies.
Avoid during pregnancy, breastfeeding, in significant heart rhythm disorders, or when quality control is uncertain.

What is Goshajinkigan?
Does it work and what benefits to expect?
How to take Goshajinkigan (dosage, timing, duration)
Who should use it, and who should avoid it?
Side effects, interactions, and quality considerations
Evidence at a glance: what studies show

What is Goshajinkigan?

Goshajinkigan (GJG; Kampo code TJ-107) is a combination of ten crude botanicals prepared to Japanese Pharmacopeia standards and manufactured as a standardized hot-water extract. The core blend derives from the kidney-yang–supporting formula Hachimi-jio-gan, with two additions (Achyranthes root and Plantago seed) that emphasize lower-body circulation and fluid dynamics.

Typical composition (by crude drug names): rehmannia root (Rehmanniae radix), cornus fruit (Corni fructus), Chinese yam (Dioscoreae rhizoma), alisma rhizome (Alismatis rhizome), poria (Hoelen), moutan bark (Moutan cortex), cinnamon bark (Cinnamomi cortex), processed aconite root (Aconiti tuber, specially detoxified), achyranthes root (Achyranthis radix), and plantago seed (Plantaginis semen). While percentages vary slightly by maker, reputable products adhere to fixed proportions and batch-to-batch standardization.

How it is thought to work (plain-language view):

Nerve excitability and pain signaling: Preclinical data suggest GJG modulates transient receptor potential (TRP) channels and kappa-opioid pathways, dampening pain signals and cold hypersensitivity.
Microcirculation and fluid movement: Several botanicals in GJG are mildly diuretic or vasomodulatory, which may reduce edema and improve nutrient delivery to nerves.
Inflammation and oxidative stress: Constituents show anti-inflammatory actions in animal models, which could protect peripheral nerves exposed to oxidative injury (as in diabetes or chemotherapy).
Muscle cramp relief: Experimental work indicates an effect on skeletal muscle sodium channels related to cramping; clinically, some people report fewer nocturnal cramps on GJG.

What GJG is—and is not: GJG is not a stand-alone cure for neuropathy. It is best considered a supportive option that may reduce symptom severity and improve comfort when combined with foundational care (glycemic control, nerve-protective medications, physical therapy, and dose management strategies in oncology).

Regulatory context: In Japan, Kampo formulas like GJG are prescription or ethical products, made from traceable crude drugs under pharmacopeial standards. Outside Japan, regulation differs. Choosing a reputable brand is therefore essential for both efficacy and safety (more on this under “Side effects, interactions, and quality considerations”).

Does it work and what benefits to expect?

Chemotherapy-induced peripheral neuropathy (CIPN):
Among supportive strategies explored for CIPN, GJG has attracted attention because it targets multiple pain pathways at once. In modern trials, prophylactic use around taxane-based chemotherapy has been associated with lower pain scores during treatment, less reliance on add-on analgesics, and fewer persistent neuropathy symptoms months later. Outcomes vary by regimen, timing, and endpoints used (patient-reported scales vs. objective measures). Importantly, where benefits are seen, they tend to reflect symptom mitigation rather than complete prevention of neuropathy.

Diabetic neuropathic symptoms and complications:
Long-term diabetic complications involve microvascular and metabolic stressors that damage nerve fibers. Kampo clinicians have used GJG to address numbness, burning pain, cold feet, and nighttime cramps. Large, pragmatic trials in type 2 diabetes suggest modest improvements in neuropathic symptoms over months of use, especially in patients with cold sensitivity or lower-limb edema. Effects on hard outcomes (e.g., incident nephropathy or retinopathy) remain uncertain, but quality-of-life and sensory symptom scores are the most consistently reported benefits.

Cold sensitivity and Raynaud-like discomfort:
Several herbs in GJG support peripheral warmth and microcirculation. People who describe “ice-cold” hands or feet—worse with damp, windy weather—sometimes report less chill, fewer pins-and-needles episodes, and better tolerance of air-conditioned environments after 4–8 weeks of steady use.

Muscle cramps and calf tightness:
Muscle cramps are common in both diabetes and following certain chemotherapies. Experimental work points to GJG’s action on muscle ion channels and local circulation, which may explain reports of fewer nocturnal cramps and quicker cramp release after dose initiation. Benefits, when present, usually appear within 2–4 weeks.

Urinary symptoms (select cases):
GJG has a traditional role in lower-urinary-tract discomfort with urgency and frequency. Early human data signal possible reductions in urgency scores without major changes in flow measures. Because the evidence base here is smaller and heterogeneous, any trial use should be time-limited with clear stop rules if no subjective improvement is seen by 6 weeks.

What to expect in practice:

Timeline: Subtle improvements often emerge within 2–4 weeks; more durable changes may require 8–24 weeks, especially with long-standing neuropathy.
Magnitude: Expect incremental relief—e.g., fewer high-pain days, reduced burning or freezing sensations, better sleep—and not total symptom disappearance.
Who benefits most: Patients with cold hypersensitivity, distal numbness/tingling, or cramp-predominant symptoms appear likelier to notice meaningful change.

Where evidence is limited or mixed: Preventing CIPN across all regimens, reversing advanced neuropathy, and modifying disease progression in diabetes are areas where results are variable. Matching regimen, timing (prophylactic vs. after onset), and duration to the clinical context is crucial.

How to take Goshajinkigan (dosage, timing, duration)

Standardized extract (granules):

Adult dose: 7.5 g/day, divided as 2.5 g three times daily, ideally before meals with warm water. This reflects the commonly used dosing in modern clinical trials and clinical practice with ethical Kampo products.
Start low if sensitive: For smaller or frail adults, or if gastrointestinal sensitivity is expected, begin at 1.25–2.5 g twice daily for 3–7 days, then increase toward the target.

Timing by goal:

CIPN prevention/mitigation (taxanes, platinum, others):

Prophylactic approach: Begin ~1 week before the first cycle or at the first signs of grade 1–2 paresthesia, and continue through chemotherapy and for 4–12 weeks afterward depending on symptoms.
Already symptomatic: If neuropathy is present, the goal is to reduce severity and analgesic needs; progress is tracked cycle by cycle.

Diabetic neuropathic discomfort:

Use daily for 12–24 weeks with reassessment every 4–8 weeks. Pair with optimal glycemic control, foot care, and—if indicated—agents like duloxetine or pregabalin.

Nocturnal cramps/cold extremities:

Trial for 4–8 weeks; continue only if a clear subjective benefit is evident (fewer night awakenings, warmer feet, less cramping).

Formulations and preparation tips:

Granules vs. decoction: Granules are pre-extracted and standardized; decoctions vary more and require expert preparation—stick to granules unless under supervision.
Consistency matters: Most benefits accrue with daily, time-consistent dosing. Set reminders or link doses to mealtimes.
Hydration and warmth: Sipping the granules in warm water is traditional and practical; maintaining hydration and foot warmth can complement the formula’s intent.

When to stop or change course:

No benefit by 6–8 weeks for cramps/cold sensitivity, or 12 weeks for neuropathic symptoms—reassess and consider tapering off.
New cough, fever, rash, shortness of breath, or rising liver enzymes—discontinue and seek medical evaluation.
Outside regulated markets: If you cannot verify product authenticity and aconite processing standards, do not use.

Practical monitoring checklist (every 4–8 weeks):

Symptom diary (numbness, pain scores, cold sensitivity episodes, sleep disruption).
Functional markers (buttoning clothes, key handling, typing, gait steadiness).
Medication burden (need for additional analgesics, dose changes).
Safety labs when appropriate (liver panel if combined with hepatically cleared drugs; electrolytes if diuretic effects cause lightheadedness).

Who should use it, and who should avoid it?

Good candidates to discuss GJG with their clinician include:

Adults undergoing taxane- or platinum-based chemotherapy who are seeking supportive options to reduce neuropathic symptom burden.
People with type 2 diabetes and distal symmetric neuropathic symptoms (burning, tingling, cold feet) who want to add a traditional formula alongside standard care.
Individuals troubled by nocturnal leg cramps or cold hypersensitivity in the hands/feet, especially when conventional strategies have been insufficient.

Use caution or avoid if:

Pregnant or breastfeeding: Safety is not established; avoid unless a specialist prescribes and monitors it.
Significant cardiac history (especially arrhythmias), seizure disorders, or severe renal/hepatic disease: Processed aconite is generally safe in regulated doses, but these conditions merit specialist oversight and a risk-benefit discussion.
Concomitant aconite-containing products or unregulated “warming” herbal blends: Increases risk without added benefit—do not combine.
Known allergy to any component herb (e.g., cinnamon bark sensitivities).
Children: Evidence is sparse; pediatric use should be specialist-guided only.

Medication interactions to consider (clinician checklist):

Neuroactive agents: Duloxetine, pregabalin/gabapentin, tricyclics—no direct antagonism expected, but overlapping sedation or dizziness warrants monitoring.
Anticoagulants/antiplatelets: Theoretical effects on circulation and platelet function from some botanicals—monitor for bruising or bleeding.
Diuretics/antihypertensives: Mild diuretic actions could modestly impact fluid status or blood pressure—track symptoms like lightheadedness.
Hepatically cleared drugs: Rare idiosyncratic liver enzyme elevations have been reported with various herbal formulas—check LFTs if adding GJG to a crowded regimen.

Shared-decision approach:
Because GJG’s benefits are modest and context-dependent, the best approach is a time-limited therapeutic trial with pre-agreed goals: what symptom will we measure, by how much, and by when? If the target isn’t met, stop and pivot.

Side effects, interactions, and quality considerations

Common experience with regulated products:
Most people tolerate GJG well. When side effects occur, they are usually mild and reversible, such as stomach upset, loose stools, nausea, or transient dizziness. These often settle by reducing the dose for a few days and taking granules with a small snack.

Less common but important events:

Elevated liver enzymes or nonspecific malaise—rare; stop and check labs.
Hypersensitivity reactions (rash, itching)—uncommon; discontinue and evaluate.
Interstitial pneumonitis has been reported with some Kampo formulas; any new cough, fever, or shortness of breath requires immediate medical review and cessation.

The aconite question—why product quality is critical:
Raw aconite contains diester diterpene alkaloids (e.g., aconitine) that are cardiotoxic and neurotoxic. In Japanese pharmacopeial GJG, aconite is processed (detoxified) and standardized, with strict identity and manufacturing controls. These controls reduce toxic alkaloids to safe levels and convert them to less toxic, analgesic forms. Poisonings linked to aconite almost always involve improper processing, mislabeling, excessive dosing, or non-regulated products.

How to protect yourself:

Choose reputable, pharmacopeia-grade products with transparent sourcing and quality testing (batch numbers, lot traceability).
Avoid compounded or self-prepared aconite products.
Do not exceed 7.5 g/day of standardized GJG extract unless a clinician directs otherwise.
Do not combine with other aconite-containing remedies or stimulant herbal blends marketed for “warming” or “circulation.”
Store properly (cool, dry place) and check expiration dates; moisture and heat can degrade botanical extracts.

When to seek help immediately:

Palpitations, chest pain, severe dizziness, fainting, new numbness spreading rapidly, facial droop, or sudden weakness.
These symptoms are not expected from appropriate GJG use; they require urgent evaluation to rule out cardiac or neurologic emergencies.

Interactions recap:
While no headline drug–herb conflicts define GJG, polypharmacy amplifies uncertainty. Share a full medication and supplement list with your care team. If you add GJG, track symptoms and labs at reasonable intervals, particularly if you’re on hepatically cleared medications or blood thinners.

Evidence at a glance: what studies show

Chemotherapy-related neuropathy

Taxane regimens (e.g., paclitaxel): In randomized, multicenter work, prophylactic GJG (7.5 g/day) was associated with lower pain scores during treatment, reduced analgesic use, and less persistent CIPN six months after chemotherapy. These benefits did not translate to differences in chemotherapy completion rates, and trials emphasized the need for placebo-controlled confirmation.
Oxaliplatin-based regimens: In a randomized, double-blind, placebo-controlled trial, TJ-107 at 7.5 g/day did not significantly reduce grade ≥2 neuropathy through cycle 8, but signals favored GJG for lower severe neuropathy rates and acceptable safety. Overall, CIPN findings are mixed, with timing (prophylactic vs. reactive) and regimen likely determining the magnitude of benefit.

Diabetic neuropathy and complications

Large, pragmatic trials in type 2 diabetes using 2.5 g three times daily have reported improvements in neuropathic symptom scores over long follow-up, though effects on macro outcomes (e.g., nephropathy, retinopathy) remain uncertain. Patients with cold hypersensitivity or lower-limb discomfort often report the clearest gains.

Mechanisms and safety

Mechanistic reviews support plausible actions on TRP channels, kappa-opioid signaling, inflammatory mediators, and microcirculation—consistent with observed reductions in pain intensity, cold sensitivity, and cramping.
Safety reviews of processed aconite underscore the importance of pharmacopeial preparation; detoxification and rigorous limits on toxic alkaloids are central to safe use. Adverse events in regulated GJG trials are uncommon and generally mild, with serious toxicity rare when standards are followed.

What this means for you

GJG is unlikely to be a “silver bullet” but may meaningfully reduce symptom burden when deployed early, consistently, and alongside standard therapies.
The highest-quality evidence favors 7.5 g/day, with weeks to months of use and clear stop criteria if benefits don’t appear.
Product quality and clinician oversight are non-negotiable, due to aconite’s inherent risks outside regulated processing.

References

Disclaimer

This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Do not start, stop, or change any medication or supplement based on this information without consulting your qualified healthcare professional, especially if you are receiving chemotherapy, have diabetes, are pregnant or breastfeeding, or have heart rhythm disorders. Product quality and proper dosing are essential for safety.

If you found this guide helpful, consider sharing it with someone who might benefit. We appreciate your support—please share on Facebook, X (formerly Twitter), or your favorite platform, and follow us for future evidence-based articles.